Note: This document contains side effect information about regorafenib. Some of the dosage forms listed on this page may not apply to the brand name Stivarga.
Common side effects of Stivarga include: infection, anemia, asthenia, diarrhea, fatigue, fever, hemorrhage, hyperbilirubinemia, hypertension, hypocalcemia, hypokalemia, hyponatremia, hypophosphatemia, increased amylase, increased inr, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum lipase, lymphocytopenia, mucositis, neutropenia, pain, palmar-plantar erythrodysesthesia, proteinuria, skin rash, thrombocytopenia, voice disorder, weight loss, and decreased appetite. See below for a comprehensive list of adverse effects.
Applies to regorafenib: oral tablet
Oral route (Tablet)
Severe and sometimes fatal hepatotoxicity has occurred with regorafenib therapy. Monitor hepatic function prior to and during therapy. Adjust dose or interrupt or discontinue therapy if hepatoxicity occurs.
Along with its needed effects, regorafenib (the active ingredient contained in Stivarga) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking regorafenib:
Some side effects of regorafenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to regorafenib: oral tablet
Very common (10% or more): Increased AST (93%), hyperbilirubinemia (78%), increased ALT (70%)
Common (1% to 10%): Acute kidney injury
Uncommon (0.1% to 1%): Severe liver injury
Frequency not reported: Hepatic failure
Very common (10% or more): Proteinuria (84%)
Common (1% to 10%): Hyperuricemia
Very common (10% or more): Anemia (79%), lymphopenia (68%), thrombocytopenia (63%), increased INR (44%), neutropenia (16%)
Common (1% to 10%): Leukopenia
Very common (10% or more): Hypophosphatemia (70%), hypocalcemia (59%), decreased appetite and food intake (47%), weight loss (32%), hypokalemia (31%), hyponatremia (30%), hypothyroidism (18%)
Common (1% to 10%): Hypomagnesemia, hypoalbuminemia
Very common (10% or more): Hand-food skin reaction/palmar-plantar erythrodysesthesia syndrome (67%), rash (30%), alopecia (24%)
Common (1% to 10%): Exfoliative rash, dry skin, nail disorder
Uncommon (0.1% to 1%): Erythema multiforme
Rare (less than 0.1%): Stevens-Johnson Syndrome, toxic epidermal necrolysis, keratoacanthoma/squamous cell carcinoma of the skin
Very common (10% or more): Asthenia/fatigue (64%), pain (60%), infection (32%), fever (28%), mucosal inflammation (17%)
Common (1% to 10%): Tinnitus, ear discomfort
Very common (10% or more): Hypertension (59%), hemorrhage (21%)
Uncommon (0.1% to 1%): Myocardial ischemia, myocardial infarction, hypertensive crisis, acute coronary syndrome
Very common (10% or more): Diarrhea (47%), increased lipase (46%), mucositis (40%), increased amylase (26%), stomatitis (25%), nausea (20%), vomiting (17%)
Common (1% to 10%): Pancreatitis, gastroesophageal reflux, gastroenteritis, dry mouth
Uncommon (0.1% to 1%): GI fistula, GI perforation
Very common (10% or more): Dysphonia (39%)
Common (1% to 10%): Epistaxis
Very common (10% or more): Headache (16%)
Common (1% to 10%): Tremor, taste disorder, peripheral sensory neuropathy, vertigo
Frequency not reported: Reversible posterior leukoencephalopathy syndrome/posterior reversible encephalopathy syndrome
Very common (10% or more): Muscle spasms (14%), musculoskeletal stiffness (14%)
Uncommon (0.1% to 1%): Hypersensitivity reaction
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Stivarga